Would you pursue adjuvant immunotherapy for a resected stage IIIC or IIID, BRAF wild type, melanoma patient with pre-existing ulcerative colitis that is well managed on maintenance infliximab?

Obviously, a challenging situation. In short, no. Risk:benefit ratio in this setting, I believe, is too high as the risk of bowel perforation is real. If recurrence does occur and surgery is not an option, can schedule infliximab infusions prior to anti-PD-1 therapy. I have been able to minimize fla...